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tisements increased awareness of new treatment (perceived
beneﬁt) and improved discussion with health professionals (per-
ceived beneﬁt) were both positively associated with switching
request (p = 0.001 and p < 0.0001, respectively). Believing that
DTC advertisements led to decreased conﬁdence in doctor’s judg-
ment (perceived barrier) was negatively associated with switch-
ing request (p = 0.02). Patients on regular medication (OR, 
2.03; 95% CI, 1.48–2.78), black patients (OR, 2.76; 95% CI,
1.48–5.13), patients with higher attentiveness to DTC advertis-
ing (p < 0.0001), and patients with allergies (OR, 1.35; 95% CI,
1.01–1.79), asthma (OR, 1.71; 95% CI, 1.09–4.33), or anxiety
(OR, 1.60; 95% CI, 1.23–2.57), were more likely to make
switching requests. CONCLUSIONS: Patients’ switching
requests were associated with health beliefs, race, health status,
and attentiveness to DTC advertising.
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POTENTIALLY INAPPROPRIATE MEDICATION PRESCRIBING
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OBJECTIVES: To investigate the prevalence of potentially inap-
propriate medication prescribing (PIP) among elderly residents
in Regione Emilia Romagna (RER), Italy and to examine factors
associated with having PIP. METHODS: We conducted a retro-
spective cohort study using the 2001 outpatient prescription
claims RER database. We linked individuals in this database with
information (age, gender, and other variables) available from a
demographic ﬁle of approximately 1 million elderly RER resi-
dents. The cohort comprised 849,425 subjects 65 years or older,
who had at least one drug prescription during the study period.
PIP was deﬁned as having a prescription claim for a medication
included in the 2003 Beers updated list of drugs to be avoided
in the elderly. Of the 48 medications in the list, 19 were reim-
bursed in 2001 by the Italian National Formulary and included
in the analysis. RESULTS: A total of 152,641 elderly in the
cohort (18.0%) had 1 or more occurrences of PIP. Of these,
11.5% received prescriptions for 2 medications of concern and
1.7% for 3 or more. Doxazosin (23.0% of the subjects) was the
most frequently occurring PIP, followed by ketorolac (20.5%),
ticlopidine (18.3%), and amiodarone (12.6%). More than half
of the PIP was for drugs with the potential for severe adverse
outcomes. Factors associated with greater likelihood of PIP were
male, older age, overall number of drugs prescribed, greater
number of chronic conditions, and lower income level. CON-
CLUSIONS: This study provides strong evidence that PIP for
elderly ambulatory patients is a substantial problem in Italy.
Because we were able to analyze only a fraction of the Beers’
drugs list, our results underestimate the extent of PIP. The aware-
ness of the prevalence of PIP and associated determinants may
be useful in designing and implementing effective programs 
targeting outpatient practitioners to inﬂuence their prescribing
behavior to reduce PIP.
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OBJECTIVES: To analyze the comparative cost effectiveness of
epoetin alfa (EPO) and darbepoetin alfa (DARB) based on the
FDA-approved doses for EPO (40,000 Units/week) and DARB
(2.25mcg/kg/week) for the treatment of chemotherapy-induced
anemia (CIA). METHODS: Clinical results were drawn from
two randomized, double blind, placebo-controlled phase III 
registration trials (EPO, N = 344 patients, JCO Sep 27, 2004
[Epub ahead of print]; DARB N = 320 patients, JNCI 2002
94:1211–20; abstract 981 Eur J Cancer 2001 37, Suppl 6: 264).
Effectiveness was based on the red blood cell transfusion rate
between Week 5 and the end of Week 12 and was standardized
as the difference in transfusion rates between the active drug 
and the respective placebo, divided by the transfusion rate for
the placebo. Estimated costs were presented in 2004 USD and
included drug, physician services, transfusions, laboratory, and
patient opportunity costs. Cost-effectiveness was calculated as
average cost divided by transfusion effectiveness. Threshold
analysis was conducted by ﬁnding the break even point at which
EPO and DARB have the same total cost and cost-effectiveness
ratio, respectively. RESULTS: Estimated total cost over 12 weeks
was $7,618 for EPO and $10,857 for DARB, with drug cost rep-
resenting 85% and 89% for EPO and DARB, respectively. Rel-
ative to placebo, the standardized transfusion effectiveness was
65% for EPO and 48% for DARB, resulting in an average cost
effectiveness ratio of $117 for EPO and $226 for DARB. A 33%
(or 54%) reduction in DARB dose or price would be needed to
equalize the total cost (or cost-effectiveness ratio) with that of
EPO. CONCLUSIONS: Drug cost was determined to be the key
driver of total cost. In addition, this analysis found EPO to be
more effective in reducing blood transfusion requirements and
less costly, and hence the dominant alternative compared to
DARB for the treatment of CIA.
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OBJECTIVES: To determine the value-for-money offered by
pemetrexed (Alimta) plus cisplatin therapy for patients with
malignant pleural mesothelioma (MPM), relative to cisplatin
monotherapy, in Australia. MPM is an uncommon, locally inva-
sive and rapidly fatal malignancy. There is currently no other
drug reimbursed by the Australian National Formulary speciﬁ-
cally for the treatment of mesothelioma. METHODS: A 
comprehensive literature search revealed one randomised head-
to-head trial of pemetrexed plus cisplatin therapy versus cisplatin
monotherapy (N = 448), by Vogelzang et al. (2003). Median 
survival for the intention-to-treat (ITT) population was 12.1
months for the pemetrexed plus cisplatin arm versus 9.3 months
for the cisplatin arm (hazard ratio = 0.77, p = 0.020). Although
there was greater toxicity with the combination regimen, quality
of life was not negatively impacted. Mean survival time for each
treatment arm was estimated from Kaplan-Meier survival curves.
Resource use was applied as per the trial and costed accordingly.
Study drug utilisation, concomitant medications, supplementary
medication (dexamethasone, folic acid, and vitamin B12), post-
study chemotherapy, and care for serious and treatment-emer-
gent adverse events were costed. RESULTS: Patients received a
mean of 4.7 treatment cycles in the pemetrexed plus cisplatin
arm, and 4.0 cycles in the cisplatin monotherapy arm. The com-
bination therapy required more supportive care for toxicities.
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The additional mean cost of pemetrexed plus cisplatin therapy,
over cisplatin monotherapy, was A$14,032.78 per patient. The
mean and median survival gain with pemetrexed plus cisplatin
therapy was found to be 0.191 and 0.233 years, respectively, rel-
ative to cisplatin monotherapy, over the 27-month period of
observation. The cost per life-year saved was A$73,470.04 for
mean and A$60,226.52 for median incremental survival. CON-
CLUSION: This survival beneﬁt is a highly patient-relevant
outcome. This economic evaluation found that pemetrexed plus
cisplatin therapy offers an acceptable cost-effectiveness ratio for
a small population of MPM patients in Australia.
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OBJECTIVES: The FDA’s approval of Avastin, Erbitux and other
novel agents has generated debate about the high cost and rela-
tive value of new cancer treatments. We sought to understand
whether oncologists consider the therapies they employ to be
cost-effective and to ascertain oncologists’ cost-effectiveness
thresholds for such therapies. METHODS: We surveyed 139
oncologists at two large academic hospitals in Boston. We asked
respondents to provide estimates for the cost and effectiveness
of Avastin (without appealing to published data) and whether
they thought the treatment offered “good value.” We also asked
respondents to judge how large a gain in life-expectancy would
justify a hypothetical new cancer therapeutic that cost $70,000
per year more than standard care. We used this information to
calculate implied cost-effectiveness thresholds (in QALYs) for
each respondent. Finally, we asked respondents about the role of
cost in their treatment recommendations. RESULTS: Ninety
oncologists (65%) completed the survey. Cost-effectiveness
thresholds, derived from the hypothetical scenario, averaged
over $300,000/QALY. Oncologists’ estimates of the cost and sur-
vival beneﬁt of Avastin implied a cost-effectiveness ratio in the
same range, yet only 25% of oncologists believed Avastin offered
good value. Oncologists who indicated a greater sensitivity to
costs in their prescribing behavior had signiﬁcantly lower cost-
effectiveness thresholds. CONCLUSIONS: Oncologists in an
academic medical setting had implied cost-effectiveness thresh-
olds that were roughly 6 times higher than a commonly cited
standard in the U.S. of $50,000/QALY. When asked about spe-
ciﬁc scenarios, however, oncologists implied that very small gains
in life expectancy were not worth the additional costs. Further,
most oncologists were dubious about whether a recently
approved therapy offered “good value.” As expensive new
cancer therapies enter clinical practice, oncologists’ views about
their role as practitioners may increasingly conﬂict with their
beliefs about the value offered by these therapies.
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Mohr P, Paserchia L, Kornﬁeld T
Centers for Medicare and Medicaid Services, Baltimore, MD, USA
OBJECTIVES: To encourage early adoption, Medicare pays a
temporary premium for selected new technologies (which are
called pass-through technologies) in the outpatient setting.
Implicit decisions are being made that the additional money
spent for these pass-through technologies is worthwhile to the
Medicare program. The goal of this study was to examine how
implicit decisions being made for pass-through technologies
compare with explicit cost-effectiveness criteria. METHODS:
We selected as case studies four technologies—two pass-through
devices (embolic capture devices and silicone oil for retinal tam-
ponade) and two pass-through drugs/biologicals (pegﬁlgrastim,
triptorelin pamoate)—that Medicare estimates will account for
the bulk of pass-through spending for 2004. We examined
whether cost-effectiveness literature existed at the time of pass-
through approval and critically examined its quality. We then
used publicly-available data (e.g., Medicare claims and payment
rates) to supplement available studies and examine cost-
effectiveness thresholds from Medicare’s perspective. RESULTS:
Cost-effectiveness studies were available for two of the four case
study technologies at the time of their application review. The
quality was variable. These studies, later publications, and our
own analyses suggest some case study technologies could be cost-
effective in at least a subset of the Medicare population in which
they are used. CONCLUSIONS: Cost-effectiveness information
is sometimes available early in the life cycle of a technology and
may provide additional useful information about whether and
for which subpopulation Medicare should pay a premium for a
new technology. Policy analysts must evaluate cost-effectiveness
information critically, however, and may need to conduct sup-
plemental analyses as a result. Medicare payment decisions do
not now reﬂect any judgment about the value of that technology
in terms of clinical beneﬁt for incremental cost. The challenge to
Medicare is to be able to limit pass-through payments to only
those populations for whom there is proven value.
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OBJECTIVES: To critically evaluate published cost-effectiveness
(CE) models and identify model elements contributing to the
large variability in results. METHODS: A literature search of
MEDLINE and EMBASE from 1985–2004 identiﬁed eight
English-language CE models comparing coxibs to a nonsteroidal
anti-inﬂammatory drug (NSAID)-alone regimen. Two studies
were excluded due to unavailable model input data. Model time
horizons ranged from six months to lifetime, and primary out-
comes ranged from gastrointestinal (GI) events averted to life-
years gained and quality-adjusted life-years gained. Common
elements across models were minor GI discomfort/dyspepsia,
moderate GI events/symptomatic ulcer, and severe GI events.
Only two of the analyses included cardiovascular side effects. To
compare model inputs we standardized all analyses to a six-
month tree structure with the three GI side effects. Study prob-
abilities were converted to six-month rates where necessary 
and costs were converted to $US using the purchasing power
parity index. Cost offsets between coxibs and NSAIDs were cal-
culated by multiplying the probability of the GI event by cost
per event. RESULTS: The relative price used for coxibs com-
pared with NSAIDs differed widely across studies (median over
six months, $156; range, $14–$387). Differences in total GI
event cost offsets were small (median, -$41; range -$53 to 
-$18). Moderate GI events provided the greatest GI event cost
